{"id":"switch-to-nortriptyline","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Urinary retention"}]},"_chembl":{"chemblId":"CHEMBL1201156","moleculeType":"Small molecule","molecularWeight":"299.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the reuptake transporters for norepinephrine and serotonin, nortriptyline increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling. This mechanism is thought to improve mood and alleviate symptoms of depression and certain pain conditions. Nortriptyline also has anticholinergic and antihistamine properties that contribute to its clinical effects.","oneSentence":"Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at neuronal synapses, increasing their availability in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:24.671Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Chronic pain conditions"},{"name":"Neuropathic pain"},{"name":"Migraine prophylaxis"}]},"trialDetails":[{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pamelor","Pamelor,"],"phase":"marketed","status":"active","brandName":"Switch to nortriptyline","genericName":"Switch to nortriptyline","companyName":"Centre for Addiction and Mental Health","companyId":"centre-for-addiction-and-mental-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at neuronal synapses, increasing their availability in the central nervous system. Used for Major depressive disorder, Chronic pain conditions, Neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}